Rabbit anti-Human PC9 Polyclonal Antibody | anti-PC9 antibody

Anti-PC9 (Paired Basic Amino Acid Cleaving Enzyme-9, PCSK9, Proprotein Convertase Subtilisin/Kexin Type 9a, NARC-1, Neural Apoptosis Regulated Convertase 1), Propeptide Domain Antibody

Cat. Num. AAA4157597

• Reactivity: Human
• Applications: Western Blot
• Purity: Immunogen Affinity Purified
• Synonyms: PC9; Polyclonal Antibody; Anti-PC9 (Paired Basic Amino Acid Cleaving Enzyme-9; PCSK9; Proprotein Convertase Subtilisin/Kexin Type 9a; NARC-1; Neural Apoptosis Regulated Convertase 1); Propeptide Domain Antibody; anti-PC9 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: The antibody recognises PCSK9 in teh region corresponding to the propeptide cleave site, and detects both the zymogen and active PCSK9.
• Purity/Purification: Immunogen Affinity Purified
• Form/Format: Liquid; PBS, pH 7.4 with 0.05% sodium azide.
• Concentration: 1ug/ul (varies by lot)

• Applicable Applications for anti-PC9 antibody: Western Blot (WB)
• Application Notes: WB: 1:1000. Predicted molecular weights: ~15 and 74 kDa. Recommended starting dilution 1:1000 with colourimetric substrates, 1:5000 with chemiluminescent substrates. Dilution optimised using Chromogenic detection.
• Immunogen: Synthetic peptide corresponding to the propeptide domain of Human PCSK9. (the amino acid sequence is considered proprietary)
• Preparation and Storage: This product is stable for several weeks at 4 degree C as an undiluted liquid. Dilute only prior to immediate use.; For extended storage, aliquot contents and freeze at-20 degree C or below. Avoid cycles of freezing and thawing. Expiration date is one (1) year from date of receipt.

Testing Data

Related Product Information for anti-PC9 antibody

Description: The antibody is a rabbit polyclonal antibody made to the subtilisin-like serine protease PC9. The antibody is made to a synthetic peptide based on the propeptide domain of human PC9. The antibody has been peptide-affinity purified, concentrated to 1.0 mg/ml, with the addition of 0.05% sodium azide as preservative and 50% glycerol as cryoprotectant. PC9 is the most recent of the human prohormone convertasae enzymes to be discovered. Also referred to as PCSK9 (proprotein convertase suntilisin/kexin type 9) and NARC-1 (neural apoptosis regulated convertase 1), PC9 is a member of the PC family of serine proteinases that cleaves after pairs of basic amino acids.PC9 and SKI-1 are two members of this larger family that do not have the paired basic amino acid requirement for cleavage. PC9 was first characterized as NARC-1, a gene up-regulated by neurons after serum withdrawal, and highly expressed in the liver and small intestine. Point mutations in PC9 were associated with autosomal dominant hypercholesteremia, and families were mapped with these different mutations (S127R and F216L in French families, D374Y in Utah and Norway). These mutations lead to increased cholesterol and LDL levels in serum, and decreased levels of LDL receptor on cell surfaces. Statin-type drugs that reduce cholesterol have been shown to upregulate PC9 expression, and thus PC9 seems to play a central regulatory role for cholesterol and LDL. Despite this, little is known about PC9 substrates. The catalytic domain has homology to other PC enzymes, the prohormone convertase family initially discovered for their role in processing POMC, insulin and other pro-hormones, and later found to process a wider range of precursor proteins. Some have renamed the prohormone convertases as proprotein convertases, and another group has renamed the entire family with a uniform nomenclature of SPCs (subtilisin-like proprotein convertases), with PC9 getting the SPC9 moniker. The PC9 structure contains a propeptide domain, a catalytic domain and an RGD containing cysteine-rich domain (homo-B). The mouse and rat sequences retain the RGD sequence, while the human and chimp sequences are modified to RGE, and the shorter PC9 sequence diverges just before the RGD sequence. The PCs have an RxxR consensus cleavage requirement, and the propeptides of the other PCs are separated from the mature protein by just such a sequence, but not so in PC9. Two forms of human PC9 are known to date; a 692 amino acid form, and a 578 amino acid form. The sequences differ in the C-terminal segment, after the catalytic domain. The 692 amino acid form has a predicted mass of 74.49 kDa, and a pI of 6.09, but glycosylation and other post-translational modifications make the pre-pro PC9 run at 78-80 kDa, the mature PC9 at 58 kDa. Smaller cleavage products_recover are also detected. The RP1PC-9 epitope crosses the propeptide cleave site, and detects both the zymogen and active PC9. A recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates.

Relevance: PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. PCSK9 may function as a proprotein convertase. PCSK9 plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in PCSK9 gene have been associated with a third form of autosomal dominant familial hypercholesterolemia.